News

Tuesday June 29, 2021

Destiny Pharma to present at Shares & AJ Bell Webinar – 6th July 2021

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma to present at the Shares and AJ Bell Investor Webinar on 06 July 2021 Brighton, United Kingdom – 29 June […]

Thursday June 10, 2021

XF-73 data abstract to be presented at 2021 ECCMID

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Data to be presented from the successful Phase 2b clinical study of XF-73 nasal gel at the prestigious 2021 ECCMID congress XF-73 […]

Monday June 7, 2021

Destiny Pharma welcomes G7’s Communique on Antimicrobial Resistance

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma welcomes G7’s Communique on Antimicrobial Resistance Highlights the global threat of the “silent pandemic” and the urgent need for the […]

Friday June 4, 2021

Result of Annual General Meeting

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Result of Annual General Meeting  Brighton, United Kingdom – 3rd June 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company […]

Wednesday June 2, 2021

Positive update on microbiome therapeutic NTCD-M3

Destiny Pharma plc (“Destiny Pharma” or “the Company”) Positive update on microbiome therapeutic NTCD-M3 for recurrent C. difficile infections · Preparations for Phase 3 study progressing to plan · Established […]